BoobyBiome, a biotechnology company focused on infant health, has secured a £1.6 million Biomedical Catalyst grant from Innovate UK. The funding will support the testing and scale-up of BoobyBiome’s Synbiotic, a product developed from breast milk to improve gut health in infants.
“We are delighted to receive this substantial grant from Innovate UK,” stated Dr. Lydia Mapstone, CEO and Co-founder of BoobyBiome. “This funding will be instrumental in advancing our research and bringing our Synbiotic closer to market, helping us provide beneficial microbes to infants at risk of developing an unhealthy gut.”
BoobyBiome’s Synbiotic is developed in collaboration with the Institute of Child Health at Great Ormond Street Hospital. It contains bacterial strains isolated from breast milk, chosen for their potential to reduce inflammation and support immune system development in infants. The University of Reading, led by Dr. Marie Lewis, will conduct comprehensive testing of the Synbiotic to prepare it for clinical trials.
“Our collaboration with the University of Reading will ensure that our product is rigorously tested and optimised, providing the best possible outcomes for infant health,” added Dr. Tara O’Driscoll, CTO and Co-founder of BoobyBiome.
In addition to the grant, BoobyBiome has attracted new investment from Evenlode Investment, Kayan Ventures, and a group of angel investors. This financial support is expected to expedite the product’s development and launch, advancing BoobyBiome’s mission to enhance infant health globally.
“We are excited to have the backing of such esteemed investors as we continue to innovate and expand our product offerings,” said Dr. Sioned Jones, COO and Co-founder of BoobyBiome. “Together, we are committed to making a positive impact on infant health globally.”
